PMID- 12141887
OWN - NLM
STAT- MEDLINE
DCOM- 20021018
LR  - 20181130
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 20
IP  - 9
DP  - 2002
TI  - Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the 
      treatment of proximal deep vein thrombosis.
PG  - 593-602
AB  - OBJECTIVE: To evaluate economic and health implications of tinzaparin sodium, a 
      once a day low-molecular-weight heparin (LMWH), versus unfractionated heparin 
      (UFH) in the treatment of acute deep vein thrombosis (DVT) from a US healthcare 
      payer perspective. STUDY DESIGN: An economic model, composed of two submodules, 
      was created: A short-term module based on clinical trial data covering the first 
      3 months and a long-term module that projects trial results based on published 
      data for up to 50 years. METHODS: Clinical trial results were combined with data 
      from long-term follow-up studies of DVT in a model that estimates the health and 
      economic consequences of treatment. Both short- and long-term costs with 
      tinzaparin sodium were compared with UFH, as were health outcomes and 
      quality-adjusted life-years (QALYs). RESULTS: Patients treated with tinzaparin 
      sodium are estimated to live a mean of 0.9 years longer on average (0.6 
      discounted), resulting in an increase of 0.8 QALYs (0.5 discounted). At the same 
      time, lifetime savings are US dollars 621 per patient (1999 values), even when 
      all patients receiving tinzapirin sodium are treated as inpatients. Early 
      discharge of patients receiving tinzaparin sodium, or outpatient treatment, would 
      save between US dollars 3000 and US dollars 5000 per patient. CONCLUSION: 
      Tinzaparin sodium leads to better health outcomes and substantial economic 
      savings compared with UFH treatment when all management costs are considered.
FAU - Caro, J Jaime
AU  - Caro JJ
AD  - Caro Research Institute, Concord, Massachusetts 01742, USA. 
      jcaro@caroresearch.com
FAU - Getsios, Denis
AU  - Getsios D
FAU - Caro, Ingrid
AU  - Caro I
FAU - O'Brien, Judith A
AU  - O'Brien JA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
RN  - 9005-49-6 (Heparin)
MH  - Ambulatory Care/economics
MH  - Clinical Trials as Topic
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Fibrinolytic Agents/economics/*therapeutic use
MH  - Health Care Costs
MH  - Health Services Research
MH  - Heparin/economics/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/economics/*therapeutic use
MH  - Hospitalization/economics
MH  - Humans
MH  - Longitudinal Studies
MH  - Models, Econometric
MH  - *Quality-Adjusted Life Years
MH  - Tinzaparin
MH  - Treatment Outcome
MH  - United States
MH  - Value of Life/economics
MH  - Venous Thrombosis/*drug therapy/*economics
EDAT- 2002/07/27 10:00
MHDA- 2002/10/19 04:00
CRDT- 2002/07/27 10:00
PHST- 2002/07/27 10:00 [pubmed]
PHST- 2002/10/19 04:00 [medline]
PHST- 2002/07/27 10:00 [entrez]
AID - 200903 [pii]
AID - 10.2165/00019053-200220090-00003 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2002;20(9):593-602. doi: 10.2165/00019053-200220090-00003.